Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3085% below fair value
$0.71+0.06 (+8.60%)
Close on Nov 13, 2026Market cap $277.71MP/E 3.2Yield –
Standard BioTools total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
For fiscal 2012 it was $0, down 100.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $0 | -100.0% |
| FY2011 | Dec 31, 2011 | $10.14M | -31.0% |
| FY2010 | Dec 31, 2010 | $14.70M | – |
See a number that looks wrong?